Leading Like a Scientist, Pitching Biotech Solutions

June 04, 2025

Illustrative photo of the Chem 7780 student team

CHEM 7780: Pharmaceutical Biotechnology instructor Assistant Professor Amy Xu (far left) with student team BioSpecific Innovations. Pictured left to right: Lauren Moore, Jen Blanchard, Hannah Saia, Mariam Afuwape, and Skyler Brown.

This past spring, students in CHEM 7780: Special Topics in Pharmaceutical Biotechnology, taught by Assistant Professor Amy Xu, were tasked with something far beyond a typical final exam: they became pharmaceutical biotechnology developers.

The biotech industry represents a compelling career path for many students, and the special topics course offers a valuable glimpse into that world. As part of a project-based experience, students took on the role of a biotech startup executive tasked with designing therapeutic strategies for real-world diseases.

The course emphasizes biotherapeutics' development, characterization, and application, including monoclonal antibodies, gene therapies, and vaccines, while mirroring the biotech sector's fast-paced, interdisciplinary, and collaborative nature.

“In CHEM 7780, students learn about pharmaceutical biotechnology through a simulated development process,” said Assistant Professor Amy Xu. “By stepping into the role of pharmaceutical biotech developers, they sharpen their skills in scientific reasoning, therapeutic design, and market analysis.” 

BioBridge mechanism by Jen Blanchard: Using recombinant DNA technology, BiTEs guide T-cells (yellow) to recognize and kill Multiple Myeloma and Leukemia cells. Engineered antibodies target cancer-specific markers, triggering apoptosis and assisting the immune system to destroy cancer cells.

BioBridge mechanism by Jen Blanchard: Using recombinant DNA technology, BiTEs guide T-cells (yellow) to recognize and kill multiple myeloma and leukemia cells. Engineered antibodies target cancer-specific markers, triggering apoptosis and assisting the immune system to destroy cancer cells.

BioSpecific Innovations Targets Cancer with BiTEs in Mock Pitch

One student team, BioSpecific Innovations, proposed an innovative immunotherapy approach using Bispecific T-cell Engagers (BiTEs). Their mock product, BioBridge, was inspired by the real science behind existing drugs and designed to target multiple myeloma and leukemia.

“Our proposed product uses recombinant DNA technology and BiTEs to treat these cancers,” explained the team’s Chief Scientific Officer, Jen Blanchard. “BiTEs are engineered molecules that act like a bridge between a patient’s immune T-cells and cancer cells. We proposed encoding antibodies onto the BiTEs that specifically recognize markers found only on multiple myeloma and leukemia cells. Once bound, the BiTEs would help direct T-cells to locate, attack, and destroy the cancer cells.”

This bridging function is what inspired the product’s name: BioBridge. “We saw it as building a bridge to health, connecting the body’s immune system directly to the cancer,” said Blanchard.

In addition to the science, the students built out the full development pipeline. “We conducted market analysis, assessed our scientific rationale, and built a pitch deck like we were presenting to investors,” said Chief Executive Officer of BioSpecific Innovation Mariam Afuwape. “It was a completely different experience from the usual paper-and-pencil exam. It pushed us to think creatively, work collaboratively, and apply our knowledge in a truly impactful way.” 

Hannah Saia, the team’s Chief Research Officer, led the development of mock clinical trials. “I learned so much about the complexities of bringing a drug to market,” she said. “Designing imaginative and scientifically grounded trials was challenging and fun.”

Skyler Brown, who held dual roles as Chief Marketing Officer and Chief Financial Officer, emphasized how the project’s creative structure enhanced her engagement. “When students are given space to be creative, learning becomes natural,” said Brown. “I got so immersed in the project that I didn’t even realize I was working on the presentation.”

Real Skills, Real Impact

By blending research, industry, and education, the course provides a valuable bridge between classroom learning and real-world scientific leadership. It gives students technical experience and confidence so that they can see themselves as future leaders in the biotech field. 

“The project confirmed that my place after grad school will be within drug discovery,” said Lauren Moore, the team’s Chief Operating Officer. “It has always been an interest, but now I can’t wait to find my place in a drug company and create the positive change we created within our project.”  

Although BioBridge was a mock proposal, the strategic thinking and professional skills cultivated through the experience were undeniably real. Starting next year, Pharmaceutical Biotechnology will be offered as CHEM 4013 and open to undergraduates, providing early exposure to the field and preparing students for future roles in biomedical innovation.